Clinical Trials
3 trialsNCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04155411 2022-07-27
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Shenzhen Second People's Hospital
Phase 4 Unknown
NCT03216070 2017-07-13
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4 Unknown